Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Sells 2,598 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) insider Oxana Beskrovnaya sold 2,598 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now directly owns 199,087 shares of the company's stock, valued at $2,777,263.65. The trade was a 1.29 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Oxana Beskrovnaya also recently made the following trade(s):

• On Wednesday, December 11th, Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock. The stock was sold at an average price of $28.12, for a total transaction of $65,632.08.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN traded up $0.44 during midday trading on Friday, reaching $13.61. 1,762,431 shares of the company traded hands, compared to its average volume of 2,267,031. Dyne Therapeutics, Inc. has a 52 week low of $12.87 and a 52 week high of $47.45. The stock has a 50-day moving average price of $16.98 and a 200 day moving average price of $27.73. The company has a market cap of $1.39 billion, a price-to-earnings ratio of -3.82 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. As a group, analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Remove Ads

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. bought a new stake in Dyne Therapeutics in the fourth quarter worth about $50,000. Neo Ivy Capital Management bought a new stake in Dyne Therapeutics in the fourth quarter worth about $205,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Dyne Therapeutics by 6.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 143,363 shares of the company's stock worth $3,378,000 after acquiring an additional 9,029 shares in the last quarter. Voloridge Investment Management LLC bought a new stake in Dyne Therapeutics in the fourth quarter worth about $2,804,000. Finally, Two Sigma Advisers LP raised its position in Dyne Therapeutics by 25.4% in the fourth quarter. Two Sigma Advisers LP now owns 76,100 shares of the company's stock worth $1,793,000 after acquiring an additional 15,400 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

DYN has been the subject of a number of research reports. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Piper Sandler decreased their price objective on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a report on Friday. Baird R W raised shares of Dyne Therapeutics to a "strong-buy" rating in a report on Thursday, December 12th. Robert W. Baird began coverage on shares of Dyne Therapeutics in a report on Friday, December 13th. They issued an "outperform" rating and a $46.00 price objective for the company. Finally, Raymond James raised shares of Dyne Therapeutics to a "strong-buy" rating in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $48.64.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.